P2Y12 inhibitors clinical trials
A class of medicines: the studies that test any of its 4 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Purinergic P2Y Receptor Antagonists.
Get an email when these change. Save the p2y12 inhibitors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Ticlopidine
- 2
Studies by the year they started
608 studies that test it; most in 2014 (58); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 3 |
| 2002 | 4 |
| 2003 | 6 |
| 2004 | 12 |
| 2005 | 8 |
| 2006 | 19 |
| 2007 | 13 |
| 2008 | 33 |
| 2009 | 33 |
| 2010 | 29 |
| 2011 | 23 |
| 2012 | 44 |
| 2013 | 42 |
| 2014 | 58 |
| 2015 | 57 |
| 2016 | 27 |
| 2017 | 36 |
| 2018 | 29 |
| 2019 | 20 |
| 2020 | 14 |
| 2021 | 20 |
| 2022 | 20 |
| 2023 | 19 |
| 2024 | 16 |
| 2025 | 11 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 124 · Other 486
AstraZeneca (43) · Sanofi (25) · University of Florida (21) · Kafrelsheikh University (14) · University of Patras (12) · Ottawa Heart Institute Research Corporation (9) · First Affiliated Hospital of Harbin Medical University (9) · The Medicines Company (9)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 610
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus BacteremiaRecruitingPhase 4Todd C. Lee MD MPH FIDSANCT06650488Written as Clopidogrel
- TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled StudyNot yet recruitingPhase 3University Hospital, ToulouseNCT07821008Written as Experimental group: ticagrelor
- The Bridging Antiplatelet Therapy With Cangrelor 2 StudyRecruitingPhase 4University of FloridaNCT07225842Written as Cangrelor
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)RecruitingPhase 4University of FloridaNCT07025148Written as Clopidogrel
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery DiseaseNot yet recruitingPhase 4University of MessinaNCT07080684Written as Ticagrelor 60 mg
- Personalizing Thromboprophylaxis for Patients With Peripheral Artery DiseaseRecruitingNot applicableMassachusetts General HospitalNCT07613840Written as Clopidogrel
- Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 MonthsRecruitingPhase 4Instituto de Investigación Sanitaria de la Fundación Jiménez DíazNCT07507500Written as Ticagrelor
- NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCIRecruitingPhase 4China National Center for Cardiovascular DiseasesNCT05638867Written as Aspirin + Clopidogrel + Rivaroxaban
- A Clinical Trial of Antiplatelets in PsoriasisNot yet recruitingPhase 4NYU Langone HealthNCT07744191Written as Clopidogrel
- Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve ImplantationRecruitingPhase 4Fundacin Biomedica Galicia SurNCT05283356Written as Ticagrelor 60mg
- A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet TherapyNot yet recruitingNot applicableFrançois MACHNCT07720934Written as Clopidogrel
- Vascular Trial Associated Registry PilotRecruitingPhase 4Corewell Health WestNCT07076082Written as Clopidogrel (Plavix) Pharmacogenetic Test Reagents
- Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal RevascularizationRecruitingPhase 3Fondation Hôpital Saint-JosephNCT07512960Written as Clopidogrel 75 mg/day
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCIRecruitingPhase 4Medical University of GdanskNCT04695106Written as Ticagrelor
- Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic StrokeNot yet recruitingPhase 4Sichuan Provincial People's HospitalNCT07644234Written as Clopidogrel
- Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of ClopidogrelRecruitingEarly Phase 1Washington State UniversityNCT06692933Written as Clopidogrel
- Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.RecruitingPhase 3Cardiocentro TicinoNCT07582835Written as Ticagrelor
- Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf CountriesNot yet recruitingPhase 3Khalid F AlhabibNCT07572747Written as Clopidgrel 75 mg daily
- AERIAL Trial: Antiplatelet Therapy in Heart TransplantationRecruitingPhase 3Ottawa Heart Institute Research CorporationNCT04770012Written as Clopidogrel
- Clopidogrel Versus Cilostazol on VesselsRecruitingPhase 4Seoul National University Bundang HospitalNCT06402747Written as Clopidogrel
Codes
What other systems call P2Y12 inhibitors · ClinicalTrials.gg INT008932
- MeSH (NLM) D058921Purinergic P2Y Receptor AntagonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D058921 | Purinergic P2Y Receptor Antagonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.